Condensed Consolidated Statements Of Cash Flows (Unaudited) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Cash Flows from Operating Activities
Net income	$ 4,785	$ 1,477
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Depreciation and amortization	3,042	2,968
Gain on sale of bioplastics manufacturing business	0	(1,453)
Share based compensation	149	353
Equity method investment (earnings) loss	(3,334)	942
Changes in operating assets and liabilities:
Restricted cash	0	12
Receivables, net	(4,050)	980
Inventory	4,042	(2,539)
Prepaid expenses	(942)	(654)
Refundable income taxes	208	(38)
Accounts payable	(3,352)	3,603
Accounts payable to affiliate, net	1,360	(3,287)
Accrued expenses	(1,951)	529
Deferred credit	(155)	(97)
Accrued retirement health and life insurance benefits and other noncurrent liabilities	(214)	(242)
Other	(230)	0
Net cash provided by (used in) operating activities	(642)	2,554
Cash Flows from Investing Activities
Additions to property and equipment	(2,182)	(798)
Proceeds from sale of bioplastics manufacturing business	0	2,797
Net cash provided by (used in) investing activities	(2,182)	1,999
Cash Flows from Financing Activities
Purchase of treasury stock	(104)	0
Principal payments on long-term debt	(384)	(426)
Proceeds from revolving credit facility	14,776	28,850
Payments on revolving credit facility	(14,321)	(32,977)
Net cash used in financing activities	(33)	(4,553)
Decrease in cash and cash equivalents	(2,857)	0
Cash and cash equivalents, beginning of year	2,857	0
Cash and cash equivalents, end of period	$ 0	$ 0